Clinical trials: FLU
Influenza Vaccine
Immunogenicity of H5N1 Vaccine Following H5N2
This study is designed to assess whether a live attenuated Influenza vaccine (LAIV) can induce a long-lasting immune memory by comparing the immunologic response to two doses of the OrniFlu® inactivated vaccine given to subjects…
- Trial name
- NCT02153671
- Testing
- A(H5N1) inactivated influenza vaccine (IIV), A(H5N2) live attenuated influenza vaccine (LAIV)
- Where
- Russia
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- PATH
Influenza
Revealing Protective Immunity to Influenza Using Systems Immunology
The goals of this study are to better understand the human immune response to influenza vaccines, specifically the live attenuated (weakened) influenza vaccine given as a nasal spray.
- Trial name
- PRISM (NCT06501963)
- Testing
- Live Attenuated Influenza Vaccine
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Emory University
Influenza
Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'
This study evaluates the immunogenicity and safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.' in healthy male and female adults at the age of 19 or older.
- Trial name
- NCT02677493
- Testing
- IL-YANG Quadrivalent Influenza Vaccine, IL-YANG Flu Vaccine Prefilled Syringe, IL-YANG Trivalent Influenza Vaccine
- Volunteers
- 1,794 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Influenza
Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine
To describe the safety during Days 0 to 21 following injection of the 2005-2006 formulation of the inactivated, split-virion influenza vaccine Fluzone in subjects aged 18-59 years and subjects aged ≥ 60 years.
- Trial name
- NCT00258830
- Testing
- Fluzone®: Influenza Virus Vaccine
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza Caused by the Novel Influenza A (H1N1) Virus
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults
The purpose of the study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults.
- Trial name
- NCT00938639
- Testing
- CSL425
- Where
- Australia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Seqirus
SARS-CoV-2, Influenza
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immunogenicity data to enable selection of an mRNA-1083 vaccine composition and dose…
- Trial name
- NCT05827926
- Testing
- Influenza Vaccine 1, mRNA-1083.1, mRNA-1083.2
- Where
- 69 sites in United States
- Volunteers
- 1,758 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the high dose quadrivalent influenza (FLU HD) vaccine in adults aged 65…
- Trial name
- NCT05559476
- Testing
- RSVPreF3 OA investigational vaccine, FLU HD vaccine
- Where
- 46 sites in United States
- Volunteers
- 1,029 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents
The present study is the first study designed to evaluate safety, tolerability and immunogenicity of the cell culture-derived influenza vaccine in healthy children and adolescents aged 3 to 17 years.
- Trial name
- NCT00645411
- Testing
- Cell culture-derived influenza subunit vaccine (cTIV), Egg derived influenza subunit vaccine (eTIV)
- Where
- 60 sites in United States, Croatia and 5 more
- Volunteers
- 3,604 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza A
A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection
The purpose of this study is to evaluate the clinical and virologic benefit of pimodivir in combination with Standard-of-Care (SOC) treatment compared to placebo in combination with SOC treatment.
- Trial name
- NCT03376321
- Testing
- Pimodivir 600 mg, SOC Treatment
- Where
- 269 sites in United States, Argentina and 36 more
- Volunteers
- 334 people
- Sponsor
- Janssen Research & Development, LLC
Influenza
Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05
Safety, Immunogenicity of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children Previously Vaccinated in Trial V118_05
- Trial name
- NCT02255409
- Testing
- Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), non-adjuvanted Quadrivalent Influenza Vaccine (QIV)
- Where
- 28 sites in United States, Finland
- Volunteers
- 607 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old
To evaluate the safety and immunogenicity of four influenza vaccines in children 6 months to < 48 months of age
- Trial name
- NCT02035696
- Testing
- Trivalent influenza vaccine (TIVc), Trivalent influenza vaccine-licensed
- Where
- 27 sites in United States, Finland and 2 more
- Volunteers
- 671 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Orthomyxovirus Infection
Influenza Vaccine Revaccination in Ambulatory Elderly Subjects
This is a multi-center study designed to evaluate the safety and immunogenicity of a Fluzone revaccination in elderly adults aged ≥ 65 years. Primary Objective: To describe the safety profile for all subjects.
- Conditions
- Influenza, Orthomyxovirus Infection, Myxovirus Infection
- Trial name
- NCT00775450
- Testing
- Influenza Virus Vaccine USP Trivalent Types A and B
- Where
- 28 sites in United States
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old
This study is designed to characterize the safety and immunogenicity of pandemic influenza (H1N1) candidate vaccines GSK2340274A and GSK234072A in children 3 to less than 10 years old.
- Trial name
- NCT01161160
- Testing
- GSK Biologicals' GSK2340274A (two different formulations), GSK Biologicals' - GSK2340272A
- Where
- 2 sites in Philippines, Thailand
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults
This multi-center study will be conducted in the United States with up to 80 healthy adult subjects. Subjects will be scheduled to receive a total of two (2) injections with 1 injection each administered.
- Trial name
- FLU-A (NCT00819013)
- Testing
- Influenza A Vaccine: ACAM FLU-A
- Where
- 3 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza A H3N2
Study Examining PrEP-001 in Healthy Subjects
Phase 2 study, looking at the prophylactic efficacy, safety and tolerability to a repeated nasal dose of study drug after being infected with Influenza A/Perth/16/2009 (H3N2) virus.
- Trial name
- NCT03220048
- Testing
- PrEP-001
- Where
- United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Hvivo
Influenza, Human
A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers
This is a study to assess the immune (antibody) response and safety of a bioCSL split virion, inactivated influenza vaccine containing the 2013/2014 formulation of Enzira® vaccine in healthy adult volunteers aged between 18 and…
- Trial name
- NCT01863433
- Testing
- Trivalent Influenza Vaccine
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults
The aim of the study is to evaluate the safety and immunogenicity of the 2011-2012 formulation of Fluzone and Fluzone High-Dose vaccines in participants aged 65 years and older.
- Trial name
- NCT01430819
- Testing
- Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation, Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation
- Where
- 6 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, SARS (Severe Acute Respiratory Syndrome)
Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)
Respiratory infections such as colds, flu and pneumonia affect millions of people around the world every year. Most cases are mild, but some people become very unwell.
- Conditions
- Influenza, SARS (Severe Acute Respiratory Syndrome), Respiratory Viral Infection, Respiratory Tract Infections
- Trial name
- PREDICT-ILI (NCT04664075)
- Testing
- Respiratory infections
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Imperial College London
Human Immunodeficiency Virus (HIV)
Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults
The goal of this study is to determine if there is a difference in shedding (primary objective) and in immunogenicity and safety (secondary objectives) between HIV-positive and HIV-negative children and young adults who are…
- Trial name
- QLAIV (NCT02474901)
- Testing
- Quadrivalent Live Attenuated Influenza Vaccine
- Where
- United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
SARS-CoV Infection, Covid19
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
This is a randomized, observer-blinded, Phase 1/2 study evaluating the safety and immunogenicity of a quadrivalent HA nanoparticle influenza and SARS-CoV-2 rS nanoparticle combination vaccine with Matrix-M1 adjuvant; this…
- Trial name
- NCT04961541
- Testing
- ICC Vaccine, qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant, SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant
- Where
- 10 sites in Australia
- Volunteers
- 637 people, healthy volunteers welcome
- Sponsor
- Novavax